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Abstract Various studies have linked different genetic
single nucleotide polymorphisms (SNPs) to different blood
lipids (BL), but whether these ‘‘connections’’ were identified
using cross-sectional or longitudinal (i.e., changes over time)
designs has received little attention. Cross-sectional and
longitudinal assessments of BL [total, high-, low-density
lipoprotein cholesterol (TC, HDL, LDL), triglycerides (TG)]
and non-genetic factors (body mass index, smoking, alcohol
intake) were measured for 2,002 Geneva, Switzerland, adults
during 1999–2008 (two measurements, median 6 years
apart), and 20 SNPs in 13 BL metabolism-related genes.
Fixed and mixed effects repeated measures linear regression
models, respectively, were employed to identify cross-sec-
tional and longitudinal SNP:BL associations among the 1,516
(76%) study participants who reported not being treated for
hypercholesterolemia at either measurement time. One-third
more (12 vs. 9) longitudinal than cross-sectional associations
were found [Bonferroni-adjusted two-tailed p \ 0.00125
(=0.05/2)/20) for each of the four ensembles of 20
SNP:individual BL associations tested under the two study
designs]. There was moderate consistency between the cross-
sectional and longitudinal findings, with eight SNP:BL
associations consistently identified across both study designs:
[APOE.2 and APOE.4 (rs7412 and rs429358)]:TC; HL/LIPC
(rs2070895):HDL; [APOB (rs1367117), APOE.2 and
APOE.4 (rs7412 and rs429358)]:LDL; [APOA5 (rs2072560)
and APOC III (rs5128)]:TG. The results suggest that cross-
sectional studies, which include most genome-wide
Electronic supplementary material The online version of this
article (doi:10.1007/s10654-012-9670-1) contains supplementary
material, which is available to authorized users.
M. C. Costanza
Department of Community Medicine and Primary Care,
University Hospitals of Geneva, University of Geneva,
Geneva, Switzerland
M. C. Costanza (&)





Section of Health, Applied R&D in Nutrition and Dietetics,
Department of Business and Administration, Health, and Social
Work, Bern University of Applied Sciences, Bern, Switzerland
e-mail: sigrid.beer@bfh.ch
R. W. James
Lipid Laboratory, Clinical Diabetes Unit,
University Hospitals of Geneva, Geneva, Switzerland
e-mail: james-richard@diogenes.hcuge.ch
J.-M. Gaspoz
Department of Community Medicine and Primary Care,




Center for the Biology of Natural Systems, Queens College,
City University of New York, New York, NY, USA
e-mail: alfredo.morabia@qc.cuny.edu
A. Morabia
Department of Epidemiology, Mailman School of Public Health,
Columbia University, New York, USA
123
Eur J Epidemiol (2012) 27:131–138
DOI 10.1007/s10654-012-9670-1
association studies (GWAS), can assess the large majority of
SNP:BL associations. In the present analysis, which was
much less powered than a GWAS, the cross-sectional study
was around 2/3 (67%) as efficient as the longitudinal study.
Keywords Association  Blood cholesterol  Cross-
sectional design  Genetic marker  Longitudinal design 
Single nucleotide polymorphism
Introduction
Concentrations of human blood lipids (BL) are, in part,
under genetic control (e.g., [1–6]). The evidence has
mainly been derived from cross-sectional associations,
which include most genome-wide association studies (e.g.,
[2–5]), that estimate how much of the between-individual
variability in BL is explained by the absence versus pres-
ence of specific alleles. The cross-sectional study design
rationale is that the BL concentrations of two groups of
subjects, assumed to be exchangeable except for an allelic
variant of interest, should differ only because of their
genetic backgrounds. This may happen either if specific
genes have an absolute impact on BL levels, or, more
likely, if they modify BL concentration changes over time.
From this perspective, cohort studies that relate genetic
traits to BL at a single point in time capture the same type
of associations as cross-sectional studies. This second type
of genetic effect may be missed in cross-sectional studies
because longitudinal differences may not necessarily
translate into differences in baseline concentrations. For
example, Chasman et al. [7] found no association between
two intronic HMG-CoA-reductase single nucleotide poly-
morphisms (SNPs) and lipid levels at baseline but an
association with lipid changes following treatment with
statins. Statins are an intervention, but BL vary with age.
The present work was designed to investigate the con-
sistency of cross-sectional versus longitudinal assessments
of the associations of 20 candidate SNPs with specific BL
[total, high, and low density lipoprotein cholesterol, and
triglycerides (TC, HDL, LDL, TG)] concentrations. These
analyses were performed in a population-based, longitu-
dinal study of adult residents of Geneva, Switzerland who
were not receiving any hypolipemic treatment.
Methods
Study sample
The study was authorized by the Institutional Review
Board of the University of Geneva, Switzerland to re-
examine 2,002 (62%) out of 3,250 randomly selected,
primarily French-speaking Geneva residents from 35 to
74 years of age. All had baseline data collected between
1999 through 2004 (Time.1) and agreed to participate in a
follow-up study conducted between 2005 and 2008
(Time.2). The sampling and recruitment methodologies
were identical to those reported elsewhere [6].
Exclusions of study participants treated
for hypercholesterolemia
Hypolipemic treatment was assessed at both points in time
by asking the study participants whether ‘‘a doctor had
prescribed a treatment to lower blood cholesterol’’. Only
those study participants who reported not being treated for
hypercholesterolemia at either time point and who had no
missing data on all BL measures and non-genetic variables
at both time points were eligible to be included in the
present cross-sectional and longitudinal analyses
(n = 1,516 (76% of 2,002) before exclusions (range:
1.3–4.3%) for missing genetic data).
Blood lipid assays
TC, HDL, and TG (mmol/L) were assayed in fasting blood
(Bayer Technicon Diagnostics, Brussels, Belgium, with
monthly quality controls performed by the Swiss Center for
Quality Control in Clinical Chemistry and Hematology).
LDL (for TG \4.52 mmol/L) was calculated as (TC-
HDL—TG/2.2) [8], and was considered missing otherwise.
To reduce (right) skewness, log(TG) was employed in most
of the subsequent statistical analyses, with corresponding
back-transformation to geometric means (GM) and various
ratios thereof in estimates and confidence intervals
(exceptions: see Table 2); for ease of presentation, the
log(TG) results are still referred to under the rubric ‘‘TG’’
below.
Genetic factors
The following rationale for selecting the genes and SNPs
was employed: 10 of the SNPs were chosen because they
belonged to seven genes involved in the reverse cholesterol
transport pathway (ABCA1, APOE, HL/LIPC, LDLR, LPL,
PLTP, SRB1), which were previously reported to be inde-
pendently associated with BL over and beyond the very
strong associations of the non-genetic factors (e.g., body
mass index, smoking, alcohol intake) [6]. In addition to the
10 SNPs of the working model, 12 more SNPs which were
identified in the interim after the latter report were selected
as good candidates: (a) apoliprotein B (APOB) (Thr71Ile,
Ala618Val, Asn4311Ser), apolipoprotein E (APOE) (Prom
-219 g/t), cholesteryl-ester transfer protein (CETP) (Prom
-971 g/a) and apolipoprotein A5 (APOA5) (ser19Trp,
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rs2072560 G/A), which were found to be strongly related
to HDL and the HDL/LDL ratio in the study of Knoblauch
et al. [9]; (b) HMG-CoA reductase SNPs 12 and 29 from
Chasman et al. [7]; (c) peroxisome proliferator-activated
receptor c (Pro12Ala) from the study of Altshuler et al.
[10]; (d) apolipoprotein-CIII (APOCIII) (rs5128 30UTR
Sst-1, rs2854116, promotor -455 C/T), which may play a
role at the interface of the metabolism of lipids, insulin,
and glucose [11–14].
All blood samples collected from 2005 through 2008
had total genomic DNA extracted from EDTA blood using
the Gentra PUREGENE DNA purification kit (BioCon-
cept, Allschwil, Switzerland).
All samples were genotyped for the following 20 SNPs
from 13 genes [SNP acronyms (rs no)]: ATP-binding cassette
protein 1 [ABCA1 (rs2777801)]; apolipoprotein A5 [APOA5
(rs2072560)]; apoliprotein B [APOB.1/APOB. 2/APOB. 3
(rs679899/rs1042034/rs1367117)]; apolipoprotein C III
[APOC3.1/APOC3.2 (rs2854116/rs5128)]; apolipoprotein E
[APOE.prom/APOE.2/APOE.4 (rs405509/rs7412/429358)];
cholesteryl-ester transfer protein [CETP (rs4783961)];
hepatic lipase (HL)/LIPC [HL.prom/HL.2 (rs2070895/
rs12909325)]; HMG-CoA (3-hydroxy-3-methyl-glutaryl-
Coenzyme A reductase) [HMG.1/HMG.2 (rs17238540/
rs17244841)]; low density lipoprotein receptor [LDLR
(rs2228671)]; lipoprotein lipase [LPL (rs328)]; phospholipid
transfer protein [PLTP (rs2294213)]; peroxisome prolifera-
tor-activated receptor c [PPARg (rs1801282)]; scavenger
receptor class B type I [SRB1 (rs5888)]. The allelic fre-
quencies of these SNPs in the untreated study participants are
shown in Table 1.
Nine of these 20 SNPs (ABCA1, APOE.2, APOE.4,
HL.prom, HL.2, LDLR, LPL, PLTP, SRB1) were assayed
twice in over n = 1,000 study participants (range:
1,036–1,077) [6, 15], with excellent reliability in terms of
gamma (range: 0.96–0.99) and kappa [simple (range:
0.82–0.95) and weighted (range: 0.83–0.95)] measures of
agreement (Supplementary Table 1).
Non-genetic factors
The five non-genetic factors (acronym) were: (SEX),
(AGE) (yrs), measured (BMI) (kg/m2), self-reported cur-
rent cigarette smoking (CSMOKE) (yes/no), and sex-spe-
cific [men/women] alcohol intake (two yes/no variables)
derived from a food frequency questionnaire [16] and
categorized using approximate gender-specific risk criteria
for daily consumption (g alcohol/day) [17]): (ALCO.L)
(low [1–40/1–20]); (ALCO.MH) (medium ? high [41?/
21?]; implied reference group (0 (none)) at the Time.1 and
Time.2 surveys.
Physical examinations included: (a) medical scale-mea-
sured weight (precision 0.1 kg) with participants lightly
dressed and without shoes (1 kg deducted across seasons to
allow for clothing); (b) medical gauge-measured standing
height without shoes (precision 0.5 cm); (c) a fasting blood
Table 1 Allelic frequencies of
the 20 SNPs assayed at the
2005–2008 (Time.2) survey for
study participants not being
treated for hypercholesterolemia
and who had no missing data on
all BL measures and non-




* Before exclusions for missing
genetic data (range: 1.3–4.3%




Nucleotide call n (%) SNP.name (rs no) Nucleotide call n (%)
ABCA1 TT/TG/GG 1,163/300/25 CETP GG/GA/AA 407/731/352
(rs2777801) (78.2/20.2/1.7) (rs4783961) (27.3/49.1/23.6)
APOA5 CC/CT/TT 1,305/175/4 HL.prom GG/GA/AA 878/504/100
(rs2072560) (87.9/11.8/0.3) (rs2070895) (59.2/34.0/6.8)
APOB.1 GG/GA/AA 393/722/336 HL.2 GG/GA/AA 507/696/279
(rs679899) (27.1/49.8/23.2) (rs12909325) (34.2/47.0/18.8)
APOB.2 AA/AG/GG 882/519/71 HMG.1 TT/TG/GG 1,399/94/3
(rs1042034) (59.2/35.3/4.8) (rs17238540) (93.5/6.3/0.2)
APOB.3 GG/GA/AA 744/590/120 HMG.2 AA/AT/TT 1,372/86/6
(rs1367117) (51.2/40.6/8.3) (rs17244841) (93.7/5.9/0.4)
APOC3.1 GG/GC/CC 572/704/215 LDLR CC/CT/TT 1,147/319/27
(rs2854116) (38.4/47.2/14.4) (rs2228671) (76.8/21.4/1.8)
APOC3.2 AA/AG/GG 1,225/255/8 LPL CC/CG/GG 1,126/327/28
(rs5128) (82.3/17.1/0.5) (rs328) (76.0/22.1/1.9)
APOE.prom CC/CA/AA 445/738/305 PLTP CC/CG/GG 1,210/260/16
(rs405509) (29.9/49.6/20.5) (rs2294213) (81.4/17.5/1.1)
APOE.2 CC/CT/TT 1,270/217/7 PPARG CC/CG/GG 1,170/305/21
(rs7412) (85.0/14.5/0.5) (rs1801282) (78.2/20.4/1.4)
APOE.4 TT/TC/CC 1,172/281/18 SRB1 CC/CT/TT 421/719/348
(rs429358) (79.7/19.1/1.2) (rs5888) (28.3/48.3/23.4)
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sample (with informed consent). Further details on the
survey measurements can be found elsewhere [6].
Statistical analyses
For assessing statistical significance of simple (unadjusted)
(Time.1–Time.2) changes in the continuous measurements
BMI and BL, two-tailed paired Student’s t tests were used
(SAS PROC TTEST [18]); for the dichotomous current
smoking and (essentially) trichotomous [none/low/(med-
ium ? high)] alcohol variables, respectively, McNemar’s
and Bowker’s v2 tests of symmetry were used (SAS PROC
FREQ [18]).
In the main statistical analyses fixed (cross-sectional
study) and mixed (longitudinal study) effects multiple
linear regression models were employed to assess the
genetic association of each SNP on the four BL outcome
variables. Each SNP was coded 0 if the rare allelic variant
was absent, or 1 if it was present (as heterozygote/homo-
zygote). This coding assumes that the rare allele effect is
dominant. The rare allele homozygote frequencies for 12 of
the 20 SNPs investigated were too small (\5%, see
Table 1) to be meaningfully analyzed assuming an additive
[0-1-2 coding for rare allele(s)] model. For the other eight
SNPs with rare allele homozygote frequencies of 100 or
more ([5%, see Table 1) individuals, additive models were
also analyzed to provide some idea of agreement with the
dominant model results.
All measurements at the Time.1 and Time.2 surveys are
identified by the suffixes ‘‘.1’’ and ‘‘.2’’. Separate analyses
were run using: (a) SAS PROC GLM [18] for fixed effects
cross-sectional linear models using the BL.2 measurements
as the outcome variables regressed (*) as:
BL:2 SEX:2 þ AGE:2 þ BMI:2 þ CSMOKE:2
þ ALCO:L:2 þ ALCO:MH:2 þ SNP;
and (b) SAS PROC MIXED [18] for mixed effects
longitudinal repeated measures (Time = 1,2) linear
models using the paired (BL.1, BL.2) (=‘‘BL’’ below,
with similar notation for the pairs of other variable)
measurements as the outcome variables regressed as:
BL SEX þ AGE þ BMI þ CSMOKE þ ALCO:L
þ ALCO:MH þ SNP þ Time þ SNP  Timef g:
To account (approximately) for multiple comparisons in
the above models, Bonferroni-adjusted, simultaneous
a = 0.05 statistical significance for the presence of any
of the 20 individual SNP associations with each of the four
individual BL as determined from the corresponding 20
cross-sectional model, or 20 longitudinal model, ensembles
of tests was claimed only when the SNP:BL association
p \ (0.05/2)/20 = 0.00125. Correspondingly, 99.75%
(Bonferroni-adjusted simultaneous 95%) confidence
intervals (CI) were employed for estimation of
LSMEANS (least squares means) of SNP absent and/vs.
SNP present subgroups adjusted for all the other non-
genetic variables in the various cross-sectional/longitudinal




Summary statistics (unadjusted) for the non-genetic factors
and the blood lipids at the cross-sectional Time.2 survey
and the mean longitudinal changes from the Time.1 to the
Time.2 surveys among the untreated study participants are
shown in Table 2. Almost all the mean longitudinal
changes examined, including those for all four BL, were
statistically significant (individual nominal p \ 0.05), even
though they were sometimes small.
SNP:BL associations
There were nine SNP:BL associations identified in the
cross-sectional models, versus 12 (33% more) identified in
the longitudinal models (Table 3). In the longitudinal
models there was little indication of any (SNP 9 Time)
interaction effects; in other words, on average the SNPabsent
and SNPpresent subgroups were very similar in terms of
within-individual BL changes (some results shown in
Table 4).
One association was observed only in the cross-sectional
study (APOB.2:TG), while four associations were found
only longitudinally: APOE.prom:TC, (CETP:HDL,
LPL:HDL), and APOE.prom:LDL.
Eight SNP:BL associations were consistently identified
across both models (Table 3): [APOE.2 and APOE.4
(rs7412 and rs429358):TC]; [HL (rs2070895):HDL];
[APOB.3 (rs1367117), APOE.2 and APOE.4 (rs7412 and
rs429358):LDL]; [APOA5 (rs2072560) and APOC3.2
(rs5128):TG].
Further results on the magnitudes and directions of the
eight SNP:BL associations consistently identified across
both study designs are provided by the point estimates with
99.75% (Bonferroni-adjusted simultaneous 95%) CIs
shown in Table 4. All six of the adjusted longitudinal
(BL.1–BL.2) differences for TC, HDL, and LDL in the
SNPabsent subgroup (Table 4) were significantly different;
that only two of those differences were significantly dif-
ferent for the (much) smaller (exceptions: APOB.3,
HL.prom) SNPpresent subgroup (Table 4) was likely due to
the smaller sample size (e.g., all six differences were in the
same direction as those of the SNPabsent subgroup). To the
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contrary, that the only longitudinal (BL.1/BL.2) geometric
mean ratio for TG (for APOA5) that differed significantly
from 1.0 occurred in the much smaller SNPpresent subgroup
(Table 4) was likely due more to violations of distribu-
tional symmetry, even after log transformation, than to
sample size issues.
All of the cross-sectional (SNPabsent-SNPpresent) differ-
ences and the (SNPabsent/SNPpresent) ratios (Table 4) were
significantly different from the respective null values 0 and
1.0. On the other hand, neither any of the longitudinal
differences of (SNPabsent-SNPpresent) differences, nor any
of the longitudinal ratios of (SNPabsent/SNPpresent) ratios,
differed significantly from the respective null values 0 and
1.0, consistent with the finding mentioned above that there
was little evidence for ant (SNP 9 Time) interaction
effects.
Dominant versus additive models
There were eight SNPs, (APOB.1, APOB. 3, APOC3.1,
APOE.prom, CETP, HL.prom, HL.2, SRB1), for which it
was feasible (rare allelic homozygotes 100 or more ([5%),
see Table 1) to compare the use of additive models (0-1-2
SNP coding) in the SNP:BL analyses instead of the dom-
inant model (0-1 SNP coding) results reported above and in
Table 3. In the cross-sectional dominant model results
(Table 3), only two of the latter eight SNPs, (APOB. 3,
HL.prom), were found to have one or more statistically
significant SNP:BL associations. On the other hand, in the
dominant model longitudinal results (Table 3), four of
those SNPs, (APOB. 3, APOE.prom, CETP, HL.prom), had
one or more statistically significant SNP:BL associations.
When, instead, additive models were employed in the
otherwise analogous cross-sectional analyses, the dominant
and additive model results were in perfect agreement in
terms of identifying statistically significant SNP:BL asso-
ciations. When additive models were employed in the
otherwise analogous longitudinal analyses, the dominant
and additive model results were almost in perfect agree-
ment, with just one very close exception for the
APOB.3:LDL associations (dominant model p =
0.0011 \ 0.00125; additive model p = 0.0029 [0.00125).
Table 2 Summaries of non-genetic factors and blood lipid (BL)
concentrations at the 2005–2008 (Time.2) survey and changes from
the 1999–2004 (Time.1) survey for study participants not being
treated for hypercholesterolemia and who had no missing data on any
of the BL measures and non-genetic variables at either time point
Non-genetic factor Cross-sectional study (Time.2) Longitudinal study changes (Time.1–Time.2)
Mean (SD) [Range] Mean (SD) [Range]
Age (years) 56.3 (10.3) [39,81]
Follow-up time (years) 5.9 (0.8) [2.3,8.0]
Subgroup n (%) % change Time.1 ) Time.2 pa
Current smoker No (N) 1,252 (82.6) N ) Y: 2.1 \0.0001
Yes (Y) 264 (17.4) Y ) N: 68.3
Alcohol None (N) 198 (13.1) N ) L: 34.8; N ) MH: 0 0.053
Low (L) 1,179 (77.8) L ) N: 6.6; L ) MH: 5.4
Med ? Hi (MH) 139 (9.2) MH ) N: 1.8; MH ) L: 51.8
Mean (SD) [P25, P75] Mean (SD) [P25, P75] pb
BMI, kg/m2) 25.0 (4.1) [22.1,27.3] 0.59 (1.59) [-0.21,1.32] \0.0001
Blood lipidb (mmol/L)
TC 5.62 (0.91) [4.98, 6.23] 0.04 (0.72) [-0.41, 0.49] 0.026
HDL 1.49 (0.38) [1.21, 1.72] 0.09 (0.26) [-0.06, 0.24] \0.0001
LDL 3.62 (0.83) [3.06, 4.16] -0.05 (0.63) [-0.45, 0.34] 0.001
TG 1.01c (0.42)c [0.75, 1.30] 0.01 (0.48) [-0.19, 0.24] 0.015
Geneva, Switzerland [n = 1,516 (men: n = 691 (45.6%); women: n = 825 (54.4%)]
TC total serum cholesterol; HDL high density lipoprotein cholesterol; LDL low density lipoprotein cholesterol; TG triglycerides
a McNemar (Current smoker) or Bowker (Alcohol) omnidirectional p value for testing the null hypothesis of off-diagonal symmetry of
proportions
b Two-tailed p value for testing the null hypothesis that the population mean = 0 with paired Student’s t test (based on log-transformed
differences for TG)
c Geometric mean; SD of log-transformed TG at Time.2
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Table 3 SNP:blood lipid
associations with p \ 0.00125






2005–2008 (n = 1,516)
Before exclusions for missing
genetic data (range: 1.3–4.3%
with missing data on individual
SNPs)
TC total serum cholesterol;
HDL high density lipoprotein




For definitions of SNP
acronyms see Table 1
Blood lipid SNP effect(s) identified in:
Cross-sectional models Longitudinal models Both models
TC 2 associations: 3 associations: 2 associations:
APOE.2, APOE.4 APOE.prom, APOE.2, APOE.4 APOE.2, APOE.4




LDL 3 associations: 4 associations: 3 associations:
APOB.3 APOB.3 APOB.3
APOE.2, APOE.4 APOE.prom, APOE.2, APOE.4 APOE.2, APOE.4




Total 9 associations 12 associations 8 associations
Table 4 SNP:blood lipid associations identified consistently across both the cross-sectional and longitudinal study designs
Blood Lipid (mmol/L) Adjusted least squares means [99.75% (Bonferroni-adjusted 95%) CI]




TC.2 APOE.2 (rs7412) Cross-sectional 5.68 (5.60, 5.75) 5.33 (5.15, 5.50) 0.35 (0.16, 0.54)
TC.1-TC.2 Longitudinal 0.11 (0.04, 0.18) 0.01 (-0.14, 0.16) 0.10 (-0.07, -0.26)
TC.2 APOE.4 (rs429358) Cross-sectional 5.58 (5.50, 5.65) 5.81 (5.65, 5.96) -0.23 (-0.40, -0.06)
TC.1-TC.2 Longitudinal 0.10 (0.03, 0.17) 0.03 (-0.10, 0.15) 0.08 (-0.07, 0.22)
HDL.2 HL.prom (rs2070895) Cross-sectional 1.45 (1.42, 1.49) 1.54 (1.50, 1.58) -0.08 (-0.13, -0.03)
HDL.1-HDL.2 Longitudinal -0.07 (-0.10, -0.04) -0.11 (-0.14, -0.07) 0.04 (-0.04, 0. 11)
LDL.2 APOB.3 (rs1367117) Cross-sectional 3.55 (3.46, 3.64) 3.72 (3.63, 3.81) -0.17 (-0.30, -0.04)
LDL.1-LDL.2 Longitudinal 0.20 (0.12, 0.28) 0.10 (0.02, 0.18) 0.10 (-0.01, 0.21)
LDL.2 APOE.2 (rs7412) Cross-sectional 3.69 (3.62, 3.76) 3.27 (3.11, 3.43) 0.42 (0.25. 0.60)
LDL.1-LDL.2 Longitudinal 0.18 (0.12, 0.24) 0.06 (-0.07, 0.19) 0.12 (-0.02, 0.27)
LDL.2 APOE.4 (rs429358) Cross-sectional 3.57 (3.50, 3.54) 3.83 (3.69, 3.97) -0.26 (-0.42. -0.10)
LDL.1-LDL.2 Longitudinal 0.17 (0.11, 0.23) 0.10 (-0.02, 0.21) 0.07 (-0.06, 0.20)
TG.2 APOA5 (rs2072560) Cross-sectional 1.00 (0.97, 1.04) 1.12 (1.03, 1.23) 0.89 (0.81 0.98)
TG.1-TG.2 Longitudinal 1.02 (0.98, 1.06) 1.04 (0.96, 1.13) 0.98 (0.88, 1.08)
TG.2 APOC3.2 (rs5128) Cross-sectional 1.00 (0.97, 1.03) 1.10 (1.03, 1.18) 0.91 (0.84, 0.98)
TG.1-TG.2 Longitudinal 1.00 (0.99, 1.06) 1.01 (0.95, 1.08) 1.01 (0.94, 1.09)
Adjusted least squares means, mean differences, and differences of mean differences (For Triglycerides, replace ‘‘means’’ by ‘‘geometric means
(GM)’’, ‘‘mean differences’’ by ‘‘GM ratios’’, and ‘‘differences of mean differences’’ by ‘‘ratios of GM ratios’’ in the previous phrase). Geneva,
Switzerland, 2005–2008
Cross-sectional: adjusted for (SEX, AGE.2, BMI.2, CSMOKE.2, ALCO.LO.2, ALCO.MH.2)
Longitudinal : adjusted for (SEX, AGE, AGE, BMI, CSMOKE, ALCO.LO, ALCO.MH)
TC total serum cholesterol; HDL high density lipoprotein cholesterol; LDL low density lipoprotein cholesterol; TG: log(TG) models and GM
used in estimates
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Discussion
The two study designs focus on assessing genetic associ-
ations with different types of outcome variables: between-
individual differences at single timepoint(s) in cross-sec-
tional studies versus within-individual changes at several
timepoints in longitudinal studies (as well as further asso-
ciations with or adjustments for changes in non-genetic
covariates).
After adjusting for multiple comparisons using a Bon-
ferroni procedure, there was moderate consistency in terms
of identifying potentially important SNP:BL associations
between the cross-sectional study (nine associations) and
the longitudinal study (12 (33% more) associations) find-
ings. These results did not appear to depend on whether
dominant (0-1 SNP coding) or additive (0-1-2 SNP coding)
models were employed in the statistical analyses. Because
eight SNP:BL associations were consistently identified
across both study designs, the cross-sectional study was
around 2/3 (8/12 = 67%) as efficient as the longitudinal
study for identifying SNP:BL associations.
It is noteworthy that the associations detected by both
designs involved well-established candidate genes such as
APOE, HL, APOB and the complex including APOA5 and
APOC III [1–6]. Other associations may require more sta-
tistical power to be detected. Teslovich et al. [5] more than
doubled (from 36 to 95) the number of identified loci for BL
when they studied [100,000 individuals instead of
*20,000. Thus, it is reasonable to expect that the consis-
tency between the two study designs would have been even
larger had our study been based on a much larger sample size.
In general, we expected both types of associations to
capture the same underlying biologic phenomena and be
consistent. We can only speculate on the reasons why some
associations failed to be reproduced in both designs. Lon-
gitudinal studies, in which BL are measured in the same
individuals at several points in time, have the advantage
over cross-sectional studies of facilitating direct assess-
ment of genetic associations on changes in BL concentra-
tions. With a cross-sectional design it is not possible to
determine whether differences between individuals are due
directly to differences in absolute concentrations of the BL,
or indirectly to differences in BL in response to aging or
behavioral changes, such as changes in weight, alcohol
intake, or smoking.
However, we cannot rule out the possibility that the
differences between the two study designs have purely
statistical causes. Firstly, longitudinal studies may have a
comparative statistical power advantage over cross-sec-
tional designs because within-individual differences over
time, though usually much smaller than between-individual
differences at a single time point, also tend to be much less
variable. This advantage may be attenuated by the
concomitant disadvantages of having to deal with mea-
surement errors at several points in time instead of just one.
Secondly, four of the eight SNP:BL associations that were
identified by both designs were in opposite directions,
which may reflect statistical instability of the estimated
regression coefficients.
The present study indicates that interpretations of
‘‘connections’’ between specific SNPs and BL concentra-
tions may not differ substantially whether evaluated cross-
sectionally or longitudinally. Any differences between the
two design approaches may be even less in GWAS, which
usually have tremendous statistical power to detect asso-
ciations in cross-sectional designs. A formal confirmation
of this conclusion in other populations is warranted.
Acknowledgments This project was supported by grants from the
Swiss National Science Foundation (N 3200-054097 and
3200-068275.02).
References
1. Bauerfeind A, Knoblauch H, Costanza MC, et al. Concordant
association of lipid gene variation with a combined HDL/LDL-
cholesterol phenotype in two european populations. Hum Hered.
2006;61:123–31.
2. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that
influence lipid concentrations and risk of coronary artery disease.
Nat Genet. 2008;40:161–9.
3. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid
levels and coronary heart disease risk in 16 European population
cohorts. Nat Genet. 2009;41:47–55.
4. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at
30 loci contribute to polygenic dyslipidemia. Nat Genet.
2009;41:56–65.
5. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical
and population relevance of 95 loci for blood lipids. Nature.
2010;466:707–13.
6. Costanza MC, Cayanis E, Ross BM, et al. Relative contributions
of genes, environment, and interactions to blood lipid concen-
trations in a general adult population. Am J Epidemiol.
2005;161:714–24.
7. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic
study of statin therapy and cholesterol reduction. JAMA.
2004;291:2821–7.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem.
1972;18:499–502.
9. Knoblauch H, Bauerfeind A, Toliat MR, et al. Haplotypes and
SNPs in 13 lipid-relevant genes explain most of the genetic
variance in high-density lipoprotein and low-density lipoprotein
cholesterol. Hum Mol Genet. 2004;13:993–1004.
10. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common
PPARgamma Pro12Ala polymorphism is associated with
decreased risk of type 2 diabetes. Nat Genet. 2000;26:76–80.
11. Hegele RA, Connelly PW, Hanley AJ, et al. Common genomic
variation in the APOC3 promoter associated with variation in
plasma lipoproteins. Arterioscler Thromb Vasc Biol.
1997;17:2753–8.
Cross-sectional and longitudinal SNP: lipid associations 137
123
12. Russo GT, Meigs JB, Cupples LA, et al. Association of the Sst-I
polymorphism at the APOC3 gene locus with variations in lipid
levels, lipoprotein subclass profiles and coronary heart disease
risk: the Framingham offspring study. Atherosclerosis.
2001;158:173–81.
13. Li WW, Dammerman MM, Smith JD, et al. Common genetic
variation in the promoter of the human apo CIII gene abolishes
regulation by insulin and may contribute to hypertriglyceridemia.
J Clin Invest. 1995;96:2601–5.
14. Olivieri O, Bassi A, Stranieri C, et al. Apolipoprotein C-III,
metabolic syndrome, and risk of coronary artery disease. J Lipid
Res. 2003;44:2374–81.
15. Morabia A, Cayanis E, Costanza MC, et al. Association of
extreme blood lipid profile phenotypic variation with 11 reverse
cholesterol transport genes and 10 non-genetic cardiovascular
disease risk factors. Hum Mol Genet. 2003;12:2733–43.
16. Morabia A, Bernstein M, Kumanyika S, et al. Development and
validation of a semi-quantitative food questionnaire based on a
population survey [French]. Soz Praventivmed. 1994;39:345–69.
17. WHO (World Health Organization). Estimating levels and pat-
terns of alcohol consumption from national surveys. In: Interna-
tional guide for monitoring alcohol consumption and related
harm. WHO, Geneva; 2000. pp. 37–62.
18. SAS Institute Inc. (Copyright 2008). SAS/STAT software,
version 9.2 of the SAS System for Microsoft Windows.
138 M. C. Costanza et al.
123
